Covalon Announces Official Launch Into Vast Latin American Market At Prestigious Hospitalar Fair & Forum, South America's Largest Medical Trade Event

MISSISSAUGA, Ontario – May 16, 2016 – /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will officially enter the vast Latin American Market at Hospitalar, Latin America's largest and most prestigious medical and healthcare trade event, taking place on May 17-20, 2016 in Sao Paulo, Brazil.

Hospitalar attracts over 90,000 visitors from North, Central and South America and is a must-attend on the agendas of hospital administrators, doctors, nurses, distributors and other industry professionals. The event is a meeting point for the healthcare chain, the ideal space for showcasing innovations in products and services.

"Latin America represents a strategic opportunity for Covalon to utilize its proven business model used in other regions, such as the Middle East, to enter the infection management, advanced wound care and surgical dressings markets within the individual countries in Central and South America" said John R. Hands, Executive Vice President of Covalon. "Hospitalar is the best place to officially launch Covalon's superior product line to the majority of the Latin American medical thought leaders. Our products are uniquely positioned to address many of the product gaps currently found in the Latin American market, especially when one considers the explosion of diabetic-related wounds in the region".

Covalon offers infection management and advanced wound management dressings for both acute and chronic wounds, including its CovaWound™ ColActive® and SurgiClear™ brands that have strong clinical evidence to support their superior efficacy in helping to prevent infections in surgical procedures and chronic diabetic foot wounds. ColActive and CovaWound when used together have the ability to rapidly promote wound closure and healing in chronic wounds, which remains an under-addressed market in Latin America.

"Our infection management and advanced wound care products have been successfully helping patients and clinicians in the United States, Middle East and Asian markets, and we are very excited about the opportunity to bring that same success to doctors and nurses in South America" said Hands. "We are in the process of engaging distribution partners in a number of Latin American countries to expand our presence in the market and we expect to accelerate this process at Hospitalar."

Covalon will also be showcasing IV Clear™ Antimicrobial Vascular Access Securement Dressing. IV Clear's combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most common hospital acquired infection bacteria[1] and SurgiClear's soft silicone adhesive will not cause adhesive related skin injury or pain during dressing changes[2].

Covalon will be showcased at the Expo Center Norte, in the North American Pavilion, Green Hall, Booth I-85 at Hospitalar, May 17-20 in Sao Paulo, Brazil.

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.

Email: bpedlar@covalon.com

Phone: 905.568.8400 x 233

Toll free: 1.877.711.6055

Web site: www.covalon.com

Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the

TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

---

https://ir.covalon.com/press-releases?item=204